ACADIA Pharmaceuticals Inc. $ACAD Stake Boosted by Fisher Asset Management LLC

Fisher Asset Management LLC grew its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 4.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 665,087 shares of the biopharmaceutical company’s stock after acquiring an additional 26,595 shares during the period. Fisher Asset Management LLC owned 0.39% of ACADIA Pharmaceuticals worth $17,764,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Dimensional Fund Advisors LP grew its holdings in shares of ACADIA Pharmaceuticals by 16.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,798,134 shares of the biopharmaceutical company’s stock valued at $59,712,000 after acquiring an additional 402,534 shares in the last quarter. Braidwell LP acquired a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at $50,760,000. Marshall Wace LLP lifted its stake in shares of ACADIA Pharmaceuticals by 19.8% in the 3rd quarter. Marshall Wace LLP now owns 2,358,881 shares of the biopharmaceutical company’s stock valued at $50,339,000 after purchasing an additional 389,170 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of ACADIA Pharmaceuticals by 390.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company’s stock valued at $35,187,000 after purchasing an additional 1,312,426 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in shares of ACADIA Pharmaceuticals by 5.7% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,547,103 shares of the biopharmaceutical company’s stock valued at $41,493,000 after purchasing an additional 84,055 shares during the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. TD Cowen lifted their price objective on shares of ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Wolfe Research assumed coverage on shares of ACADIA Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $33.00 price objective for the company. Stifel Nicolaus reduced their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating for the company in a research note on Thursday, February 26th. Mizuho raised shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $29.00 to $35.00 in a research note on Monday, February 23rd. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.63.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock opened at $21.19 on Thursday. The firm has a market cap of $3.63 billion, a price-to-earnings ratio of 9.63, a P/E/G ratio of 25.74 and a beta of 0.86. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $19.69 and a fifty-two week high of $28.35. The firm has a fifty day moving average price of $21.69 and a two-hundred day moving average price of $23.83.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The firm had revenue of $268.10 million for the quarter, compared to analyst estimates of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The firm’s revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.11 EPS. As a group, sell-side analysts expect that ACADIA Pharmaceuticals Inc. will post 0.39 earnings per share for the current year.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, insider James Kihara sold 5,401 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the transaction, the insider owned 24,509 shares of the company’s stock, valued at $519,100.62. The trade was a 18.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Mark C. Schneyer sold 3,506 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $21.79, for a total transaction of $76,395.74. Following the transaction, the executive vice president directly owned 66,145 shares of the company’s stock, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 13,978 shares of company stock valued at $302,819. Company insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.